Ibrutinib, an oral covalent inhibitor of
Bruton's tyrosine kinase, is an effective
therapy for patients with
chronic lymphocytic leukemia (CLL). To determine whether
rituximab provides added benefit to
ibrutinib, we conducted a randomized single-center trial of
ibrutinib vs
ibrutinib plus
rituximab. Patients with CLL requiring
therapy were randomized to receive 28-day cycles of once-daily
ibrutinib 420 mg, either as a single agent (n = 104), or together with
rituximab (375 mg/m2; n = 104), given weekly during cycle 1, then once per cycle until cycle 6. The primary end point was progression-free survival (PFS) in the intention-to-treat population. We enrolled 208 patients with CLL, 181 with relapsed CLL and 27 treatment-naive patients with high-risk disease (17p deletion or TP53 mutation). After a median follow-up of 36 months, the Kaplan-Meier estimates of PFS were 86% (95% confidence interval [CI], 76.6-91.9) for patients receiving
ibrutinib, and 86.9% (95% CI, 77.3-92.6) for patients receiving
ibrutinib plus
rituximab. Similarly, response rates were the same in both arms (overall response rate, 92%). However, time to normalization of peripheral blood lymphocyte counts and time to complete remission were shorter, and residual disease levels in the bone marrow were lower, in patients receiving
ibrutinib plus
rituximab. We conclude that the addition of
rituximab to
ibrutinib in relapsed and treatment-naive high-risk patients with CLL failed to show improvement in PFS. However, patients treated with
ibrutinib plus
rituximab reached their remissions faster and achieved significantly lower residual disease levels. Given these results,
ibrutinib as single-agent
therapy remains current standard-of-care treatment in CLL. This trial was registered at www.clinicaltrials.gov as #NCT02007044.